TY - JOUR T1 - Interactive web application for plotting personalized prognosis prediction curves in allogeneic hematopoietic cell transplantation using machine learning JF - medRxiv DO - 10.1101/2019.12.14.19014654 SP - 2019.12.14.19014654 AU - Hiroshi Okamura AU - Mika Nakamae AU - Shiro Koh AU - Satoru Nanno AU - Yasuhiro Nakashima AU - Hideo Koh AU - Takahiko Nakane AU - Asao Hirose AU - Masayuki Hino AU - Hirohisa Nakamae Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/01/14/2019.12.14.19014654.abstract N2 - Background Allogeneic hematopoietic cell transplantation (allo-HCT) is a curative treatment option for malignant hematological disorders. Transplant clinicians estimate patient-specific prognosis empirically in clinical practice based on previous studies on similar patients. However, this approach does not provide objective data. The present study primarily aimed to develop a tool capable of providing accurate personalized prognosis prediction after allo-HCT in an objective manner.Methods We developed an interactive web application tool with a graphical user interface capable of plotting the personalized survival and cumulative incidence prediction curves after allo-HCT adjusted by eight patient-specific factors, which are known as prognostic predictors, and assessed their predictive performances. A random survival forest model using the data of patients who underwent allo-HCT at our institution was applied to develop this application.Results We succeeded in showing the personalized prognosis prediction curves of 1-year overall survival (OS), progression-free survival (PFS), relapse/progression, and non-relapse mortality (NRM) interactively using our web application (https://predicted-os-after-transplantation.shinyapps.io/RSF_model/). To assess its predictive performance, the entire cohort (363 cases) was split into a training cohort (70%) to develop the predictive model and test cohort (30%) to confirm its performance time-sequentially. The areas under the receiver-operating characteristic curves for 1-year OS, PFS, relapse/progression, and NRM in test cohort were 0.70, 0.72, 0.73, and 0.77, respectively.Conclusions The new web application could allow transplant clinicians to inform a new allo-HCT candidate of the objective personalized prognosis prediction and facilitate decision-making.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the Japan Society for the Promotion of Science (JSPS) KAKENHI Grant (number 17K09017).Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets generated during and/or analyzed during the current study are not publicly available due to the ethically sensitive nature of the research. Although they may be provided by the corresponding author on reasonable request, its request must be submitted to the Research Ethics Committee in our hospital and be approved.ADTreealternating decision treeallo-HCTallogeneic hematopoietic cell transplantationAUCarea under the receiver-operating characteristic curveCBcord bloodCIconfidence intervalCox PHCox proportional hazardDRI-Rrefined disease risk indexEBMTEuropean Group for Blood and Marrow TransplantationGITMOItalian Group for Bone Marrow TransplantationGUIgraphical user interfacehaplo-PBhaploidentical peripheral bloodHCT-CIhematopoietic cell transplantation comorbidity indexHLAhuman leukocyte antigenMACmyeloablative conditioningNRMnon-relapse mortalityOSoverall survivalPFSprogression-free survivalPSperformance statusrBMrelated bone marrowRICreduced intensity conditioningrPBrelated peripheral bloodRSFrandom survival forestuBMunrelated bone marrow ER -